Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
Sponsor: MBX Biosciences
Summary
The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.
Official title: A Randomized, Double-blind, Placebo-controlled First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of MBX 4291 in Adult Participants With Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2025-09-03
Completion Date
2026-05-30
Last Updated
2025-12-15
Healthy Volunteers
No
Conditions
Interventions
MBX 4291
MBX 4291 will be administered subcutaneously (SC)
Placebo
Placebo: Placebo will be administered subcutaneously (SC)
Locations (1)
MBX Biosciences Investigational Site
Knoxville, Tennessee, United States